Despite macroeconomic concerns, currency headwinds and related cost inflation, Boston Scientific Corporation BSX is seeing strength across target markets. The company is demonstrating growth backed by ...

The company’s third-quarter earnings report for fiscal 2024 showed strong sales growth and adjusted per-share earnings of ...

Boston Scientific BSX is slated to report fourth-quarter fiscal 2024 results on Feb. 5 before market open. See the Zacks Earnings Calendar to stay ahead of market-making news. For fourth-quarter ...

I had high expectations for Boston Scientific going into 2024 – at ... and other less-celebrated businesses like urology and peripheral vascular continue to perform well. As far as dangers ...

Boston Scientific Corp. engages in the development ... The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral ...

The company primarily operates through its MedSurg (endoscopy, urology, and neuromodulation ... a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp ...